## Background: Tumor markers are putative prognostic indicators for patients with carcinoma, but have not heretofore been evaluated in patients with stage ii and iii pancreatic carcinoma. ## Methods: Patients with stage ii (n=9) and stage iii (n=25) unresectable regional adenocarcinoma of the pan
Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma
β Scribed by William G. Dilley; Darrow E. Haagensen; George S. Leight; Sheree Ammirata; Sara R. Davis; John S. Silva; Norman Zamcheck; Jacob J. Lokich; Samuel A. Wells
- Publisher
- Springer US
- Year
- 1986
- Tongue
- English
- Weight
- 882 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Women with metastatic breast carcinoma have a highly variable clinical course and outcome. Intrinsic genetic heterogeneity of the primary breast tumor may play a role in this variability and may explain it in part. Therefore, the authors tested the hypothesis that the cha
## Abstract We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19β9, CA 15β3, CA 125, Ξ²βchorionic gonadotropin (Ξ²βHCG) and Ξ±βfetoprotein (AFP) were related with the histological pattern (
Sera samples from 111 women, including 73 breast cancer patients and 38 patients with benign diseases of the breast, were examined. These were compared with samples from healthy women or from patients carrying tumors of origin other than breast as controls. This was done to determine whether antibod